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Summary 
T  cells  are made tolerant  only to  those self-peptides that  are presented in sufficient amounts 
by antigen-presenting cells. They ignore cryptic self-determinants,  such as either those not generated 
by processing machinery or generated in insufficient amounts. It is anticipated that mechanisms 
that either change antigen processing or increase the yield of previously "invisible" peptides may 
be capable of inducing T cell priming and, if they are stir-maintained,  may sustain autoimmune 
diseases.  Herein,  we demonstrate for the first time a mechanism by which the gpl20 human 
immunodeficiency virus-I, by downregulating plasma membrane CD4 and increasing its processing, 
unveils hidden  CD4 epitopes,  inducing  an autoimmune-specific  T  cell response. 
T  cell tolerance to self-antigens  is sustained either by elimi- 
nation  of self-reactive T  lymphocytes in  the  thymus 
(clonal deletion) or through peripheral tolerance mechanisms, 
such as clonal anergy or downregulation of TCR (1, 2). Both 
mechanisms are dependent on the ability of APC to process 
self-peptides, and the capacity of a self-determinant  to bind 
with high affinity the MHC molecules (immunodominant 
peptide) and to be consequently recognized by specific auto- 
reactive T cells (3). Therefore, normally naive (virgin) T cells, 
specific for "invisible" self-determinants, ignore them for lack 
of a productive "meeting"  The precise events by which an 
"invisible"  self-antigen  become "visible"  for  the  immune 
system are not dear, although different mechanisms have been 
implicated in this phenomenon. For example, it has been sug- 
gested that either cross-reactive non-self-antigens, complexes 
of self- and non-self-antigens,  infections, or general inflam- 
matory  processes  may  alter  the  self-antigen  processing, 
facilitating  the generation and presentation of previously cryp- 
tic T  cell epitopes (4-8). 
Here, we demonstrate a novel mechanism by which a viral 
antigen,  such as the HIVgpl20,  unveils hidden  CD4 pep- 
tides by changing CD4 processing, thus making them "visible" 
to autoreactive specific  T  cells. 
Materials  and Methods 
Reagents.  Soluble recombinant  CD4 and gpl20 proteins, ex- 
pressed in CHO cells and bacolovims, respectively, were purchased 
from Intracel Corp. (Cambridge, MA). The analogous CD4 pep- 
tides were synthesized by solid-phase method on an automated mul- 
tiple peptide synthesizer (AMS 422; Aimed, Langenfeld, Germany) 
using F-moc chemistry. The purity of peptides was determined by 
reverse-phase HPLC. Peptides were diluted to a concentration  of 
2 mg/ml and stored at  -20~ 
The following anti-CD4 mAbs were used for CD4 modulation: 
6D10 (9), 10A12 (10, 11), and OKT4B (12) are specific for V1, 
V1-2,  and V2-3  domains  of CD4,  respectively. The  following 
anti-class II mAbs were used for the blocking experiments: anti- 
DP (lgG1,  B7.21), anti-DQ (IgG2a,  SPVL3), anti-DR (IgG2a, 
L243). FITC-labded second antibodies and OKT4-FITC were pur- 
chased from Southern Biotechnology Associates (Birmingham, AL) 
and Ortho Diagnostic  Systems, Inc. (Raritan,  NJ), respectively. 
Cell fluorescence was analyzed with the FACScan  |  flow cytometer 
(Becton Dickinson  & Co., Mountain  View, CA). 
Cell Culture~  Antigen-specific  T cell clones and EBV-transformed 
B cell lines were isolated and maintained as previously described 
(12). EBV-B cells or T  cell clones, used  as APC,  were  pulsed 
(4 h) with different concentrations  of recombinant  soluble CD4, 
washed, and irradiated (13,000 and 3,000 tad, respectively). Alter- 
natively, APC were pulsed overnight with increasing concentra- 
tions of either  recombinant  gpl20 or different anti-CD4  mAbs. 
APC (5  ￿  104) were then cultured for 72 h with 3  ￿  104 antigen- 
specific cloned T cells in 200/~1 RPMI-10% FCS (Hyclone Labora- 
tories Inc., Logan, UT) in flat-bottomed microtiter plates (Falcon 
Plastics, Cockeysville, MD) in triplicate. 18 h before harvesting the 
cultures,  1 /zCi [3H]thymidine (Amersham  Corp.,  Amersham, 
UK) was added and the radioactivity incorporated by cells deter- 
mined as described (12). Cloned T cells, used as APC, were taken 
up no more than 6-10 d after the last stimulation,  when they can 
efficiently present soluble antigens (13). In some experiments, the 
presenting T cells were pulsed with either anti-CD4 mAbs or gpl20, 
washed, stained with OKT4-FITC, and analyzed with direct im- 
munofluorescence using  a FACScan  | 
Results and Discussion 
Recently, we demonstrated that peripheral blood T lym- 
phocytes of some HIV-infected patients proliferate in response 
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Figure  2.  APC endogenously expressing CD4 can efficiently present 
soluble CD4, but are unable to spontaneously stimulate CD4-specific T 
cells. Proliferative  response of CD4-specific T cell clone CP12 (,4) to three 
independent autologous CD4 + T  cell clones (0,  ~,  O),  previously 
pulsed with increasing concentrations of soluble CD4; (B) to increasing 
numbers of the same CD4 § APC, which were not pulsed with antigen. 
Cultures were set up and T cell proliferation measured after 48 h as de- 
scribed in Materials and Methods. 
to a soluble form of the CD4 molecule (data not shown). 
Fig. I shows representative T cell clones, generated from one 
such CD4-responsive individual, proliferating in response to 
increasing concentrations of CD4 (Fig.  1, A-C) in the con- 
text of HLA-DP,11  allele (Fig.  1, D-F).  Indeed,  CD4 pre- 
sentation  is  strongly  inhibited  only  by  anti-DR  mAb  in 
blocking experiments,  and particularly among a large panel 
of homozygous EBV-B cell lines with known haplotype, only 
those  DR1101 +  or  DRl104 +  are  able  to  present  soluble 
CD4.  In addition,  the fine specificity study,  using overlap- 
ping synthetic peptides spanning the entire CD4 molecule, 
demonstrates that the clones recognize two adjacent peptides 
(amino acids 73-88 and 81-96, respectively; Fig. 1, G-/). We 
wondered whether  these clones were able to recognize not 
only CD4 peptides generated by processing of exogenous CD4 
molecules, but also those derived from plasma membrane CD4 
since it may be internalized by CD4 § cells and sorted to the 
endocytic pathway  (14-16). 
Fig.  2 A  shows  that irrelevant  autologous  CD4 §  T  cell 
clones, used as APC, are able to present soluble CD4, as well 
as autologous EBV-B cells (Fig.  1), confirming that human 
class  II +  T  cells,  particularly when  recently activated,  can 
e~ciently capture and present soluble antigens (13). On the 
contrary, activated T cells, although expressing CD4, are un- 
able to present it and can present only exogenous CD4, demon- 
strating that in normal conditions the epitopes derived from 
both plasma membrane and endogenous CD4 are not gener- 
i 
o  10 
CL 
o  8 
I  6 
o 
,4 
,'9-  2 
E 
~  0 
I" 
c~-m~  e 
=  .....  ,  "  i~, 
~i  zA,t  Fh~M,e  16  A 
8 
4 
i  i  m  I  --  0 
0.1  1  10  100 
gp120 (~,g/m  0 
3t  ~ 
~  i~,  1r  i~  i~ 
B  /. 
/ 
￿9  I  -3  I  ~2  I  --I 
0  10  10  10 
Anti-CD4  mAb  (dilutions) 
Figure  3.  Modulation of membrane CD4 on presenting T cells leads 
to productive CD4 processing and presentation. The figure shows a repre- 
sentative experiment on proliferative  responses of CD4-specific T cell clone 
CP12 to (A) autologous cloned CD4 + T cells (0), cloned CD8 + T cells 
(O), or CD4- EBV-B cells (V), previously pulsed (overnight) with in- 
creasing concentrations of recombinant gp120; (B) autologous cloned 
CD4 + T cells (0), cloned CD8 § T cells (O), or CD4- EBV-B cells (V), 
previously pulsed (overnight) with increasing dilutions of anti-CD4 mAb 
supernatant (IgG1, 6I)10) recognizing the V1 domain of CD4.  Analo- 
gous results were obtained using either 10A12 or OKT4B mAbs recog- 
nizing V1-2 and V2-3, respectively, or the CD4-specific CP50 clone as 
effector cells. Cultures were set up and T cell proliferation measured after 
48 h as described in Materials and Methods. The upper half of the figure 
shows the flow cytometric analysis of CD4 modulation on cloned CD4 + 
T cells, previously pulsed with (a) 0 (1), 1 (2), or 10 (3)/xg/ml gp120; 
(b) 10 -3 (I), 10 -2 (2), or 10 -1 (3) dilutions of anti-CD4 mAb (6D10). 
Then, cells were stained with OKT4-FITC mAb and analyzed by direct 
immunolluorescence using a FACScan  | 
ated  during  processing  (Fig.  2  B).  It is possible,  however, 
that in conditions  in which  membrane CD4 is downregu- 
lated, the immunogenic CD4 peptides may be generated in 
sufficient amounts and be efficiently presented on class II mol- 
ecules to CD4-specific T  cells. To evaluate the possibility that 
membrane CD4 processing could be altered by amplifying 
CD4 internalization (3, 6, 17-20), we tested the APC efficiency 
of autologous  activated  CD4 +  T  cells,  which  were  previ- 
ously pulsed with increasing concentrations of either soluble 
HIVgp120 antigen  or anti-CD4  mAbs, both of which  can 
drastically downregulate plasma membrane CD4 on cells (Fig. 
3, a and b). More important,  Fig. 3 shows that CD4 § APC 
pulsed with either gp120 or anti-CD4  mAb effectively ac- 
quire the capacity to stimulate a CD4-specific T  cell clone 
in a dose-dependent fashion, indicating that the modulation 
Figure  1.  Antigen-specific proliferative response of class II-restricted T cell clones to a soluble form of CD4 molecule and fine specificity studies. 
(A-C) Proliferative response of three representative T cell clones (CP12, CP20, and CPS0) derived from a CD4 responder individual (HLA A3, 10 
[26]; B18, 51; Cw5; DR5 [111; DQ3) to increasing concentrations of soluble CD4, presented by an autologous EBV-B cell line. (D-F) HLA restriction 
of CD4-specific T cell clones, using as APC either autologous EBV-B cells (in the presence or absence of different anti-class II mAbs) or a series of 
homozygous EBV-B cell lines with known haplotype, previously pulsed (solid ba~) or not (open bars) with soluble CD4. (G-/) Fine specificity  of CD4- 
specific T cell clones. CD4-specific T cell clones were cultured with autologous EBV-B cells in the presence or absence of synthetic overlapping 16-mer 
peptides spanning the entire CD4. The sequence of stimulatory peptides are as follows: peptides 73-88 (PSKLNDRADSR.P.SLWD); peptides 81-96 
(DSRRSLWDQGNFPLII). 
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ligands leads to a more diident internalization and to changes 
in CD4 processing.  In contrast,  autologous CD4-  APC, 
like EBV-B cells or cloned CD8 + T  cells, although pulsed 
with the same reagents, are incapable of inducing the prolifer- 
ation of CD4-specific T cells, ruling out the possibility that 
the response was caused by cross-reactive Peptides generated 
by processing of gp120 or anti-CD4 mAbs (Fig. 3). In addi- 
tion, CD4 + APC, which were previously pulsed with an ir- 
relevant mAb, such as the antitransferrin receptor (CD71), 
which  is  known  to  modulate its  own  membrane ligand 
on  cells  (19),  do  not  stimulate  the  CD4-specific  T  cells 
(not shown). 
Experiments on antigen processing reveal that both chlo- 
roquine treatment and glutaraldehyde fixation of presenting 
CD4 + T cells drastically abrogate the capacity of APC func- 
tion, supporting the notion that membrane CD4 is processed 
through the endocytic pathway (Table  1).  Recently, it has 
been reported that class II molecules available for peptide 
loading are selectively confined to spedalized class II-con- 
raining vesicles (CIIV) of APC, which appear only partially 
accessible to endosomal content (21-24). Since membrane CD4 
has been suggested to spontaneously enter CIIV, presumably 
directed by a dilencine motif (15, 25-27), the enhanced in- 
ternalization of membrane CD4 by its own ligands may more 
effadently dictate its  localization  to  CIIV,  increasing the 
efficiency of antigen processing and presentation. 
In conclusion, our results indicate that in normal condi- 
tions,  the immunogenic CD4 peptides derived from both 
membrane and endogenous CD4 are not generated in suffident 
amount during processing, and the CD4-specific T cells re- 
main in a state of ignorance in the periphery. In contrast, 
either gp120 or anti-CD4 mAb, increasing the delivery of 
membrane CD4  into  the endocytic pathway of activated 
CD4 + T  cells, and maybe of more specialized  CD4 + APC 
(28), allow the generation of an increased yield of previously 
invisible  CD4 peptides available to bind class II molecules 
and to prime naive CD4-specific dass II-restricted T  cells. 
Table  1.  Processing Requirement for Membrane CD4 
Presentation by CD4 § APC 
Time after pulsing 
and before fixation  [3H]Thymidine uptake by T cells 
rain  cpm 
0  280 
30  325 
120  11,625 
120 + chloroquine  774 
Cloned CD4 + T cells, as APC, were pulsed at 0~  with an'ti-CD4 mAb 
for 30 min, washed, and cultured at 37~  for the times indicated before 
fixation with 0.05% glutaraldehy~ (Sigma Chemical Co., St. Louis, MO). 
In some experiments, prepulsed APC were incubated at 37~  with 100 
/~M chloroquine (Sigma Chemical Co.). APC were then cultured with 
CP12 T cell clones, and T cell proliferation was measured after 48 h, as 
described  in Materials  and Methods. 
These data suggest a new pathogenetic mechanism in some 
AIDS patients in which both the high blood concentrations 
of gp120 (29) and the anti-CD4 autoAbs (30-32) may operate 
as previously discussed, triggering an autoimmune T cell re- 
sponse against CD4 + cells (e.g., T cells, dendritic cells, mac- 
rophages) taking part in the severe dysfunction of these cells 
(33,  34).  The T  cell response to CD4 could be started by 
HIVgp120 and sdf-perpetuated, irrespective of the presence 
of gp120, by a vicious circle maintained by anti-CD4 autoAbs 
sensitizing  CD4 +  APC  to  activate CD4-spedfic T  ceils, 
which in turn may boost the production of anti-CD4 autoAbs. 
Finally,  our results may represent a general model of an- 
toimmunity,  suggesting  that  a  non-stir-antigen,  such  as 
gp120, altering the processing of a stir-antigen (in:., the CD4), 
can  unveil hidden immunogenic sdf-peptides,  awakening 
specific autoreactive T  and B cells from their lethargy. 
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